Suicidality Risk With ADHD Drugs Should Be Treated As Class Effect – Cmte.
Executive Summary
The risk of suicidality in children receiving drugs to treat attention deficit/hyperactivity disorder should be viewed as a class effect, FDA's Pediatric Advisory Committee recommended March 22
You may also be interested in...
Sparlon Is In Strattera Stratum With Regard To Efficacy, Committee Says
Efficacy of Cephalon's attention deficit/hyperactivity disorder drug Sparlon should be considered to be in the range of Lilly's Strattera, FDA's Psychopharmacologic Drugs Advisory Committee said March 23
ADHD Drug Warnings In New Highlights Section Replaces Need For Black Box
The ability to highlight warnings under FDA's new labeling rule may obviate the need for a "black box" warning against risks associated with attention deficit/hyperactivity disorder drugs, FDA's Pediatric Advisory Committee suggested March 22
ADHD Drug Warnings In New Highlights Section Replaces Need For Black Box
The ability to highlight warnings under FDA's new labeling rule may obviate the need for a "black box" warning against risks associated with attention deficit/hyperactivity disorder drugs, FDA's Pediatric Advisory Committee suggested March 22